Articles On Imagion Biosystems (ASX:IBX)

ASX recovers from session lows of -0.91pc to fall -0.13pc Info tech, commodities weakness undercut market Banks, defensive sectors mount resistance ASX battens down the hatches It was looking like we were in for another 90-point routing...

Imagion Biosystems (ASX: IBX) has received positive results on dosage tests in preparation for a Phase 2 clinical trial of HER2 breast cancer imaging agent MagSense.

October marks Global Breast Cancer Awareness Month with several ASX companies working to advance early detection and treatments for better outcomes Imagion’s first-of-its-kind imaging agent tech MagSense uses targeted nanoparticles to enha...

ASX slides 24.6 points with 10 of 11 sectors lower Materials sector squeaks into green on gold gains Resources stocks limit broad losses Gold miners do the hard yards The ASX 200 moved broadly lower today, down 0.27% on general market we...

Manufacturing completed on Imagion’s MagSense HER2 breast cancer imaging agent for its Phase II clinical trial Imagion, Siemens and Wayne Street University AI imaging protocol optimisation collaboration progressing, with results to be inc...

After five months of consecutive gains, the ASX 200 fell 0.78% in September with nine of 11 sectors in the red Smaller companies performed strongly with the ASX Emerging Companies and ASX Small Ordinaries rising 13% and 3% respectively Emb...

Current cancer imaging tools are “not good enough”, Imagion chief Bob Proulx says Micro-x announces second grant in the space of two days Race Oncology wins Korean trial assent … in South Korea, of course   Imagion Biosystems (ASX:IBX) sa...

Down, down, prices were down for the ASX this week … but TFFF (Thank something for Friday) as we rebounded (slightly) into weekend Expert analyst Guy Keller chimes in with his three stock picks  And this week’s Stockhead ‘Hot Stock’? Find...

Good afternoon, and welcome to the HotCopper HotList Top 10. Every week, hundreds of companies go through the ups and downs of the ASX trading rollercoaster, with fortunes made and equity lost each time the Aussie bourse opens – which is wh...

Pitt Street Research says Imagion is significantly undervalued and sits around 75-80% below target range of 12.3 to 14.9 cents per share Research house sees further upside if MagSense imaging agent tech progresses to commercialisation in a...

Cervical cancer detection play Truscreen says its year is off to a good start PYC Therapeutics enters “transformational period” … as does Imagion Biosystems   Trans-Tasman cervical screening outfit Truscreen Group (ASX:TRU) has promised a...

ASX closes 0.24% lower on Monday with tech leading gainers and energy the laggards Asian markets climb higher led by Tokyo after Japanese Prime Minister Shigeru Ishiba announces resignation Supermarket giants Coles and Woolworths face heft...

Imagion Biosystems (ASX: IBX) has commenced manufacturing of its MagSense imaging agent ahead of a Phase 2 HER2 breast cancer clinical trial to start in the US before year end. The agent will assess axillary nodal disease in patients diagno...

Imagion Biosystems (ASX:IBX) has started manufacturing its MagSense HER-2 imaging agent ahead of a Phase 2 breast cancer trial later this year.  The company is also preparing an Investigational New Drug Application with the FDA in America,...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Dimerix boss Dr Nina Webster to join Imagion Biosystems as non-executive director Webster has extensive experience with ASX healthcare companies and is also non-executive chair of SYNthesis BioVentures Appointment comes as Imagion prepares...

  In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several compa...

Imagion to collaborate with MRI experts at Wayne State University to strengthen push into AI-enabled cancer diagnostics Collaboration will establish optimised imaging protocols for Imagion’s MagSense molecular-imaging-agent tech Bolsters...

Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow   There’s a long d...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Imagion Biosystems (ASX:IBX) chairman Robert Proulx and company advisor Dr Leonardo...

Imagion secures $3.5 million in capital raise to sophisticated investors and family offices Placement to support ongoing clinical program for MagSense Imaging agent for cancer Company currently preparing to undertake Phase II trial in HER2...

Copper prices crash 20pc Materials sector undercuts market, down 2.57pc Info tech rally not enough to push ASX into positive territory   Tech rally fails to lift resources The ASX staged a steady recovery through the day to finish down ju...

 Plenty of biotechs are lodging late in the piece, but without too many ‘dog ate my homework’ excuses Telehealth group looks to post-pandemic recovery   Botanix, Amplia and Vitrafy pass muster with the brokers   Some students hand in thei...

ASX hits new record closing high of 8630 points Broad strength across 10 of 11 sectors, led by info tech Rio Tinto appoints Aussie Simon Trott as new CEO ASX closes almost 30 points higher than previous record The ASX 200 surged to a new...

Imagion Biosystems (ASX: IBX) has announced it will fast-track a new batch of MagSense HER2 imaging agent ahead of a Phase 2 breast cancer trial this year. The decision follows a meeting with the US Food and Drug Administration where Imagio...

Imagion holds positive meeting with senior US FDA staff on planned Phase II clinical trial for HER2 breast cancer Company plans to submit investigational new drug application for MagSense HER2 imaging agent in Q3 CY25 Renowned surgical onc...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

ASX shrugs off tariff pessimism to climb 0.59pc Gains led by gold and banking stocks Major banks join RBA stablecoin project   Gold and Banks lead ASX charge Let’s see – a 50% tariff on copper, up to 200% on pharmaceuticals, and maybe mor...

Trigg Minerals (ASX:TMG) has drawn the most attention on the HotCopper forums through Thursday trade after the mining company mysteriously halted just before open. Holders were left “a bit worried” across the boards. Listen to the HotCop...

Imagion receives positive feedback from US FDA for HER2 breast cancer phase II clinical trial The company’s share price on the ASX has rallied early, more than 90%, with more than 100m shares traded Imagion’s clinical team set to meet with...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

Certain ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety and efficiency in healthcare For example, Imricor is pioneering cardiac ablations using MRI instead of traditional x-ray fluoroscopy t...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Imagion Biosystems (ASX:IBX) executive chair Bob Proulx.     There are a few ways to...

Stockhead’s Fraser Palamara chats with Imagion Biosystems (ASX:IBX) executive chairman Robert Proulx to discuss the company’s cancer-detecting imaging agent technology. Fraser and Robert discuss the current state of the technology, difficul...

A number of ASX-listed healthcare companies, many with relatively low market caps, are making strides in tackling cancer Imagion is  aiming to revolutionise cancer diagnosis by introducing molecular imaging to magnetic resonance imaging (M...

Cancer detection specialist Imagion Biosystems (ASX: IBX) has taken the next step in progressing its MagSense HER2 imaging agent, lodging an application with the US Food and Drug Administration (FDA). The application for initiated manufactu...

Manufacturing to start on new batch of Imagion’s MagSense HER2 breast cancer imaging agent The new batch intended for use in phase II study to be proposed to US FDA in an Investigational New Drug application Imagion has previously made tw...

Early detection and treatment can improve prognosis for cancer patients Several ASX biotechs looking to improve early cancer diagnostics and medical treatment Optiscan’s technology brings surgeons and pathologists together to facilitate ea...

Imagion Biosystems to use funds from $3m capital raise to advance MagSense platform technology Through MagSense, Imagion aims to revolutionise cancer diagnosis by introducing molecular imaging to MRI The company is pursuing initial indicat...

Cancer drug developer Chimeric Therapeutics eyes minimum $5 million raising ‘The next Telix’, Clarity gets FDA go-ahead for prostate cancer trial LTR Pharma fleshes out erectile dysfunction trial results   Cancer cell therapy house Chimer...

ASX gains  as energy and mining stocks rally Arcadium Lithium surges  after Rio acquisition, while GYG reports strong Q1 Hurricane Milton lands and pushes oil prices higher   The ASX gained ground by 0.3% on Thursday and neared its recor...

Imagion raises $3 million to advance its MagSense platform MagSense is designed to revolutionise cancer diagnosis by introducing molecular imaging to MRI Strong support for the placement from a broad range of high-quality sophisticated in...

ASX fell as mining stocks dropped on China’s lack of stimulus Brent oil dipped below US$80 Big lithium stocks fall, but smaller players keep gaining after Rio Tinto’s Arcadium takeover talks   The ASX closed lower by 0.35% in a volatile...

Good morning! ASX futures were up 0.28 per cent at 8:30 am AEDT after a fairly uninspiring US session. The major US indexes ended flattish on either side of the deciding line with the S&P 500 down 0.01 per cent; the Dow up 0.04 per...

An already buoyant ASX boosted past +1.1% on happy CPI data for May. Consumer Discretionary just pipped by Real Estate, both up more than 2.1%. Stellar Resources takes line honours after hitting fresh zinc finds in Tassie.   A pleasing ba...

“I am thrilled to be leading the Imagion team and look forward to driving the company’s continued success with new solutions for cancer patients and their care teams,” said new CEO, Dr Isaac Bright.

Aussie markets are down 0.6% after the gubbermint dropped an unpopular look at the future. Gold stocks, Energy, Materials, Resources, Metals and miners are all well below the broader market. Iris Metals bucked the trend, out of the ASX dog...

The ASX closed 0.6 per cent lower on news Australia is likely to be hit with a mid-year slowdown. Investment bank UBS released data from a survey conducted over the second half of May. The figures showed a decline in the financial outloo...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX is tracking negatively so far, down by 0.3 per cent at midday, with the biggest gainers being the real estate and healthcare sectors. In ASX news, Imagion Biosystems (IBX) has initiated plans to close its clinical study after ach...